0000000000496211

AUTHOR

Christoph Schumacher

showing 2 related works from this author

EORTC-1203: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive stomach cancer—INN…

2016

TPS4133Background: Approximately 10-20% of patients with gastric cancer (GCa) have HER-2 positive tumors. The addition of T to cisplatin/fluoropyrimidine-based CT improved survival in metastatic HE...

OncologyCisplatinCancer Researchmedicine.medical_specialtybusiness.industryImproved survivalCancermedicine.disease03 medical and health sciences0302 clinical medicineOncologyTrastuzumab030220 oncology & carcinogenesisInternal medicinePerioperative chemotherapymedicine030211 gastroenterology & hepatologyPertuzumabStomach cancerbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

The role of panitumumab in combination with ECX in perioperative chemotherapy of unselected patients with locally advanced gastroesophageal adenocarc…

2015

4040 Background: Perioperative chemotherapy (pCT) significantly improved survival of patients (pts) with locally advanced esophagogastric adenocarcinoma (la EGC). However, ~60% of pts will later di...

OncologyCancer Researchmedicine.medical_specialtybusiness.industryLocally advancedPhases of clinical researchImproved survivalCancermacromolecular substancesmedicine.diseaseSurgerycarbohydrates (lipids)stomatognathic diseasesOncologyInternal medicinePerioperative chemotherapyotorhinolaryngologic diseasesmedicinebacteriaPanitumumabAdenocarcinomabusinessmedicine.drugJournal of Clinical Oncology
researchProduct